- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Opko gains $295 million up front for global license to develop, market long-acting HGH.
Amgen plans to expound on plans for the company at its Oct. 28 investor meeting.
Cash, stock $12.2 billion deal would solidify BD position in infection control, respiratory care.
Perrigo gains women's health assets, Amag Pharmaceuticals buys Makena line in the transaction.
The unsolicited bid comes a week after the Pennsylvania target announced a plant to cut 30% of its workforce.
Teaneck, N.J.-based information technology solutions company Cognizant Technology Solutions is adding the operations of TriZetto to create a fully integrated healthcare technology and operations leader.
As more companies seek tax savings through inversions, strategic reasons still remain for drug company deals.
Fresh from AstraZeneca plc's rebuff of its $117 billion offer, Pfizer is setting its sights on a much smaller deal in the U.S. by acquiring InnoPharma.
Target produces radiofrequency ablation systems, boosting the buyer's pain management business.
Building on the M&A trend for tax inversion deals, Salix Pharmaceuticals and Italy's Cosmo Pharmaceuticals plan to merge.